SOURCE: Power of the Dream Ventures, Inc.

Power of the Dream Ventures, Inc.

April 11, 2011 09:20 ET

Power of the Dream Ventures, Genetic Immunity Announces Positive Phase II Data for DermaVir HIV therapeutic Vaccine; Results Show 70% Viral Load Reduction

BUDAPEST, HUNGARY--(Marketwire - Apr 11, 2011) - Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to announce Genetic Immunity's Phase II trial results for the Company's Lead Product candidate called DermaVir, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.

DermaVir, the world's first topical dendritic cell-targeting HIV therapeutic vaccine candidate, employs nanotechnology to boost the patient's own immune responses and to kill HIV-infected cells. The goal of DermaVir immune boosting therapy is to decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.

In a randomized, placebo-controlled, dose-ranging Phase II study conducted in Hamburg, Germany, thirty-six HIV-infected individuals, not yet taking antiretroviral drugs, received one of three DermaVir doses, or the placebo, every six weeks. "The treatments were very well-tolerated and CD4+ cell counts did not decrease," explained the study's Principle Investigator, Jan van Lunzen, MD of the University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit. "At 24 weeks, the individuals' HIV viral loads were compared to their baseline values. A statistically significant reduction of 0.5 log10copies/mL, a 70 percent reduction equivalent to that produced by several anti-HIV drugs, was seen in the cohort receiving 0.4 mg DermaVir vaccinations. Also in this group, HIV gag-specific precursor/memory T cells increased by 97 percent as the viral load decreased, a result not seen with antiretroviral drugs. Based upon our study the immune boosting and antiviral activity of DermaVir immunizations may provide a unique treatment approach for people with HIV/AIDS."

DermaVir features all key technological elements of Genetic Immunity's Immune Therapy Technology Platform. The Active Pharmaceutical Ingredient of DermaVir is a single plasmid DNA immunogen safely expressing 15 HIV antigens, the broadest antigen repertoire seen among HIV vaccine candidates to date. DermaVir Product is a "pathogen-like" nanomedicine and it is administered topically with a medical device, called DermaPrep. This technology in vivo targets the antigens to dendritic cells to prime naïve T cells and expand the HIV-specific T cell pool to kill HIV-infected cells.

"Unlike traditional vaccines that prevent disease, therapeutic vaccines are given to people who are already infected to boost the body's immune response. To live a better and longer life, HIV-infected people boost their immune systems with vitamins, dietary supplements and herbs. We designed DermaVir to specifically boost their immune system to kill their HIV-infected cells and win the battle. Our Phase II trial provides the human proof of concept that immune boosting with DermaVir can reduce HIV viral load by killing the infected cells," said Julianna Lisziewicz, PhD and CEO of Genetic Immunity.

About PDV
Power of the Dream Ventures, Inc. is a leading technology holding company. We identify and harness the unique technological prowess of Hungary's high-tech industry, turning promising ideas and ready to market products/technologies into global industry leaders. We focus on developing, acquiring, licensing, or co-developing technologies that originate exclusively in Hungary that are in prototype stage based on existing patents; in prototype stage prior to patenting; existing products that require expansion capital to commercialize; emerging science and high-technology research projects that require help in patenting, developing the product and marketing, University spin-off technologies, and ideas from the very early stage that represent "disruptive technologies." For more information, please visit

About Genetic Immunity

Genetic Immunity is a privately held US/Hungarian biotechnology company developing a new class of immunotherapeutic biologics for the treatment of viral infections, cancer and allergy. The Company's proprietary Immune Therapy Technology Platform is based on dendritic cell-targeting topical nanomedicines. For more information please visit

About DermaVir

DermaVir is a novel therapeutic HIV vaccine with both antiviral and immunomodulating activities. Genetic Immunity believes that DermaVir has the potential to offer a paradigm change in the treatment of HIV/AIDS based on clinical data showing boosting of HIV-specific T cells and decrease of HIV-infected cells that are not eliminated by antiretroviral drugs. DermaVir has an excellent safety profile similar to vaccines used in healthy adults and children. The goal of DermaVir immune intensification is to modify HIV disease, decrease drug exposure while maintaining undetectable HIV-RNA levels and achieve remission (functional cure) in HIV-infected patients.

Contact Information

  • Contact:
    At Power of the Dream Ventures:

    Viktor Rozsnyay
    President and CEO
    Phone: +36-1-456-6061
    Fax: +36-1-456-6062
    US telephone: 1-646-499-4510 between 8AM and 1PM EDT.

    At Genetic Immunity:

    Dr. Zsolt Lisziewicz
    Chief Operating Officer
    Phone: +36-1-272-0364
    Fax: +36-1-272-0365
    Cell: +36-30-211-6402